[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.7314/APJCP.2015.16.6.2129

Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment

Goldar, Samira (Department of Biochemistry and Clinical Labratorary, Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences)
Khaniani, Mahmoud Shekari (Department of Biochemistry and Clinical Labratorary, Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences)
Derakhshan, Sima Mansoori (Department of Biochemistry and Clinical Labratorary, Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences)
Baradaran, Behzad (Immunology Research Center, Tabriz University of Medical Sciences)

Publication Information

Asian Pacific Journal of Cancer Prevention / v.16, no.6, 2015 , pp. 2129-2144 More about this Journal

Abstract

Programmed cell death (PCD) or apoptosis is a mechanism which is crucial for all multicellular organisms to control cell proliferation and maintain tissue homeostasis as well as eliminate harmful or unnecessary cells from an organism. Defects in the physiological mechanisms of apoptosis may contribute to different human diseases like cancer. Identification of the mechanisms of apoptosis and its effector proteins as well as the genes responsible for apoptosis has provided a new opportunity to discover and develop novel agents that can increase the sensitivity of cancer cells to undergo apoptosis or reset their apoptotic threshold. These novel targeted therapies include those targeting anti-apoptotic Bcl-2 family members, p53, the extrinsic pathway, FLICE-inhibitory protein (c-FLIP), inhibitor of apoptosis (IAP) proteins, and the caspases. In recent years a number of these novel agents have been assessed in preclinical and clinical trials. In this review, we introduce some of the key regulatory molecules that control the apoptotic pathways, extrinsic and intrinsic death receptors, discuss how defects in apoptotic pathways contribute to cancer, and list several agents being developed to target apoptosis.

Keywords

Apoptosis; apoptotic pathways; cancer; treatment target;

Citations & Related Records

Times Cited By KSCI : 3 (Citation Analysis)

Reference
Cited By KSCI

1	Hassan M, Watari H, AbuAlmaaty A, et al (2014). Apoptosis and molecular targeting therapy in cancer. Biomed Res Int, 2014, 150845.
2	Hassen S, Ali N, Chowdhury P (2012). Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. World J Gastrointest Pathophysiol, 3, 71-9. DOI
3	Hawkins CJ, Silke J, Verhagen AM, et al (2001). Analysis of candidate antagonists of IAP-mediated caspase inhibition using yeast reconstituted with the mammalian Apaf-1-activated apoptosis mechanism. Apoptosis, 6, 331-8. DOI
4	Hernandez A, Wang QD, Schwartz SA, et al (2001). Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg, 5, 56-65. DOI
5	Herrero Martin D, Boro A, Schafer BW (2013). Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma. PLoS One, 8, 55072. DOI
6	Hinds MG, Norton RS, Vaux DL, et al (1999). Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat Struct Biol, 6, 648-51. DOI
7	Hong B, van den Heuvel AP, Prabhu VV, et al (2014). Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets, 15, 80-9. DOI
8	Hotte SJ, Hirte HW, Chen EX, et al (2008). A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res, 14, 3450-5. DOI
9	Hu Q, Wu D, Chen W, et al (2013). Proteolytic processing of the caspase-9 zymogen is required for apoptosome-mediated activation of caspase-9. J Biol Chem, 288, 15142-7. DOI
10	Lima RT, Busacca S, Almeida GM, et al (2011). MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer, 47, 163-74. DOI ScienceOn
11	Liu G, Kelly WK, Wilding G, et al (2009). An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res, 15, 3172-6. DOI
12	Liu Z, Li H, Derouet M, et al (2005). ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem, 280, 37383-92. DOI
13	Liu Z, Li H, Wu X, et al (2006). Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells. Oncogene, 25, 7680-90. DOI
14	Longley DB, Wilson TR, McEwan M, et al (2006). c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene, 25, 838-48. DOI
15	Lu J, McEachern D, Sun H, et al (2011). Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther, 10, 902-14. DOI
16	Lucas DM, Davis ME, Parthun MR, et al (2004). The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 18, 1207-14. DOI
17	Martinez-Caballero S, Dejean LM, Kinnally MS, et al (2009). Assembly of the mitochondrial apoptosis-induced channel, MAC. J Biol Chem, 284, 12235-45. DOI
18	Matthew S. Davids M (2013). The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. american society of hematology [Epub ahead of print].
19	O'Brien S, Moore J, Boyd T, et al (2009). 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol, 5208-12.
20	Nemunaitis J, Ganly I, Khuri F, et al (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res, 60, 6359-66.
21	Oliner JD, Pietenpol JA, Thiagalingam S, et al (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-60. DOI
22	Oltersdorf T, Elmore SW, Shoemaker AR, et al (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-81. DOI
23	Ouyang L, Shi Z, Zhao S, et al (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 45, 487-98. DOI ScienceOn
24	P: C (2001). p53 as a drug target in cancer therapy. Expert Opin Ther Patents, 923-35.
25	Park SJ, Kim MJ, Kim HB, et al (2009). Trichostatin a sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol, 77, 1328-36. DOI
26	Pathil A, Armeanu S, Venturelli S, et al (2006). HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology, 43, 425-34. DOI ScienceOn
27	Tabernero J, Dirix L, Schoffski P, et al (2011). A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res, 17, 6313-21. DOI
28	Svane IM, Pedersen AE, Johansen JS, et al (2007). Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother, 56, 1485-99. DOI
29	Svane IM, Pedersen AE, Johnsen HE, et al (2004). Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother, 53, 633-41. DOI
30	Szegezdi E, Logue SE, Gorman AM, et al (2006). Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep, 7, 880-5. DOI
31	Tagscherer KE, Fassl A, Campos B, et al (2008). Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene, 27, 6646-56. DOI
32	Tajeddine N, Galluzzi L, Kepp O, et al (2008). Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene, 27, 4221-32. DOI
33	Tanioka M, Nokihara H, Yamamoto N, et al (2011). Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol, 68, 505-11. DOI
34	Tchoghandjian A, Jennewein C, Eckhardt I, et al (2013). Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis, 4, 564. DOI
35	Vermeij R, Leffers N, van der Burg SH, et al (2011). Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol, 2011, 702146.
36	Vande Walle L, Lamkanfi M, Vandenabeele P (2008). The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ, 15, 453-60. DOI
37	Varfolomeev E, Blankenship JW, Wayson SM, et al (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell, 131, 669-81. DOI
38	Venza I, Visalli M, Oteri R, et al (2014). Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol, 21, 439-46. DOI
39	Vici P, Mariani L, Pizzuti L, et al (2014). Emerging biological treatments for uterine cervical carcinoma. J Cancer, 5, 86-97. DOI ScienceOn
40	Wacheck V, Heere-Ress E, Halaschek-Wiener J, et al (2001). Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med (Berl), 79, 587-93. DOI
41	Wakelee HA, Patnaik A, Sikic BI, et al (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol, 21, 376-81. DOI
42	Wang S, Zhao Y, Bernard D, et al (2012). Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. Springer Berlin Heidelberg??, 57-79.
43	Wang Y, Lee CG (2009). MicroRNA and cancer--focus on apoptosis. J Cell Mol Med, 13, 12-23.
44	Micheau O (2003). Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets, 7, 559-73. DOI
45	Mawji IA, Simpson CD, Gronda M, et al (2007a). A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res, 67, 8307-15. DOI
46	Mawji IA, Simpson CD, Hurren R, et al (2007b). Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst, 99, 811-22. DOI
47	Menon AG, Kuppen PJ, van der Burg SH, et al (2003). Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther, 10, 509-17. DOI
48	Micheau O, Lens S, Gaide O, et al (2001). NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol, 21, 5299-305. DOI
49	Min KJ, Seo BR, Bae YC, et al (2014). Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death Dis, 5, 1063. DOI
50	Mirza A, McGuirk M, Hockenberry TN, et al (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21, 2613-22. DOI
51	Mukhopadhyay S, Panda PK, Sinha N, et al (2014). Autophagy and apoptosis: where do they meet? Apoptosis, 19, 555-66. DOI
52	Nakahara T, Kita A, Yamanaka K, et al (2007). YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res, 67, 8014-21. DOI
53	Plati J, Bucur O, Khosravi-Far R (2011). Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb), 3, 279-96. DOI
54	Pei XY, Dai Y, Grant S (2004). The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther, 3, 1513-24.
55	Perez LE, Parquet N, Meads M, et al (2010). Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol, 84, 212-22. DOI
56	Philchenkov A, Zavelevich M, Kroczak TJ, et al (2004). Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol, 26, 82-97.
57	Prezma T, Shteinfer A, Admoni L, et al (2013). VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis, 4, 809. DOI
58	Qiu J, Gao Z, Shima H (2012). Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis. Oncol Rep, 27, 160-7.
59	Rao-Bindal K, Koshkina NV, Stewart J, et al (2013). The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets, 13, 411-22. DOI
60	Reesink-Peters N, Hougardy BM, van den Heuvel FA, et al (2005). Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol, 96, 705-13. DOI
61	Roy MJ, Vom A, Czabotar PE, et al (2014). Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol, 171, 1973-87. DOI
62	Riley JS, Hutchinson R, McArt DG, et al (2013). Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death Dis, 4, 951. DOI
63	Rohn JL, Noteborn MH (2004). The viral death effector Apoptin reveals tumor-specific processes. Apoptosis, 9, 315-22. DOI
64	Rossi MN, Antonangeli F (2014). LncRNAs: New Players in Apoptosis Control. Intern J Cell Biology, 2014.
65	Rudin CM, Hann CL, Garon EB, et al (2012). Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res, 18, 3163-9. DOI
66	Safa AR, Day TW, Wu CH (2008). Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets, 8, 37-46. DOI
67	Safa AR, Pollok KE (2011). Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers (Basel), 3, 1639-71. DOI
68	Saleem M, Qadir MI, Perveen N, et al (2013). Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des, 82, 243-51. DOI ScienceOn
69	Schimmer AD, Thomas MP, Hurren R, et al (2006). Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res, 66, 2367-75. DOI
70	Sevrioukova IF (2011). Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal, 14, 2545-79. DOI
71	Shin JS, Ha JH, Chi SW (2014). Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy. Biochem Biophys Res Commun, 443, 882-7. DOI
72	Sharma S, de Vries EG, Infante JR, et al (2014). Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs, 32, 135-44. DOI
73	Shiau CW, Yang CC, Kulp SK, et al (2005). Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res, 65, 1561-9. DOI
74	Shin H, Lee YS, Lee YC (2012a). Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncol Rep, 27, 1111-5.
75	Shin JS, Ha JH, He F, et al (2012b). Structural insights into the dual-targeting mechanism of Nutlin-3. Biochem Biophys Res Commun, 420, 48-53. DOI ScienceOn
76	Shirley S, Micheau O (2013). Targeting c-FLIP in cancer. Cancer Lett, 332, 141-50. DOI
77	Shoshan-Barmatz V, De Pinto V, Zweckstetter M, et al (2010). VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med, 31, 227-85. DOI
78	Shoshan-Barmatz V, Mizrachi D (2012). VDAC1: from structure to cancer therapy. Front Oncol, 2, 164.
79	Sikic BI et al (2007,). A phase Ib study toassess the safety of lexatumumab, a human monoclonal antibody thatactivates TRAIL-R2, in combination with gemcitabine, pemetrexed,doxorubicin or FOLFIRI.
80	Singh R, Saini N (2012). Downregulation of BCL2 by miRNAs augments drug-induced apoptosis-a combined computational and experimental approach. J Cell Sci, 125, 1568-78. DOI
81	Spierings DC, de Vries EG, Vellenga E, et al (2004). Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem, 52, 821-31. DOI
82	Song JH, Song DK, Herlyn M, et al (2003). Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res, 9, 4255-66.
83	Sosin AM, Burger AM, Siddiqi A, et al (2012). HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol, 5, 57. DOI
84	Speetjens FM, Kuppen PJ, Welters MJ, et al (2009). Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res, 15, 1086-95. DOI
85	Subramaniam K, Hirpara JL, Tucker-Kellogg L, et al (2013). FLIP: a flop for execution signals. Cancer Lett, 332, 151-5. DOI
86	Sun H, Kapuria V, Peterson LF, et al (2011). Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood, 117, 3151-62. DOI
87	Sun H, Liu L, Lu J, et al (2010). Cyclopeptide Smac mimetics as antagonists of IAP proteins. Bioorg Med Chem Lett, 20, 3043-6. DOI
88	Sun Y, Peng ZL (2009). Programmed cell death and cancer. Postgrad Med J, 85, 134-40. DOI
89	Sung B, Park B, Yadav VR, et al (2010). Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem, 285, 11498-507. DOI
90	Tiberio P, Cavadini E, Abolafio G, et al (2010). 4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells. PLoS One, 5, 13362. DOI
91	Tolcher AW, Mita M, Meropol NJ, et al (2007). Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol, 25, 1390-5. DOI
92	Tolcher AW, Quinn DI, Ferrari A, et al (2012). A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol, 23, 968-73. DOI
93	Touzeau C, Dousset C, Le Gouill S, et al (2014). The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia, 28, 210-2. DOI
94	Travert M, Ame-Thomas P, Pangault C, et al (2008). CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol, 181, 1001-11. DOI
95	Trudel S, Stewart AK, Li Z, et al (2007). The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res, 13, 621-9. DOI
96	Vaillant F, Merino D, Lee L, et al (2013). Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell, 24, 120-9. DOI
97	Van Poznak C, Seidman AD, Reidenberg MM, et al (2001). Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat, 66, 239-48. DOI
98	Wei Y, Fan T, Yu M (2008). Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai), 40, 278-88. DOI
99	Watanabe K, Okamoto K, Yonehara S (2005). Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ, 12, 10-8. DOI
100	Wea RA (2012). Selective inhibition of BCL-2 is active against chronic lymphocytic leukemia (CLL): first clinical experience with the BH3-mimetic ABT-199. Haematologica, 97, 257-8.
101	Weyhenmeyer B, Murphy AC, Prehn JH, et al (2012). Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol, 34, 192-9.
102	Whitehead KA, Langer R, Anderson DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov, 8, 129-38. DOI
103	Wright CW, Duckett CS (2005). Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest, 115, 2673-8. DOI
104	Wu HH, Wu JY, Cheng YW, et al (2010). cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res, 16, 5200-10. DOI
105	Wuilleme-Toumi S, Robillard N, Gomez P, et al (2005). Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia, 19, 1248-52. DOI
106	Xiao C, Srinivasan L, Calado DP, et al (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol, 9, 405-14. DOI
107	Yuan S, Akey CW (2013). Apoptosome structure, assembly, and procaspase activation. Structure, 21, 501-15. DOI
108	Yamabe K, Shimizu S, Ito T, et al (1999). Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther, 6, 1952-9. DOI
109	Yang L, Cao Z, Yan H, et al (2003). Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res, 63, 6815-24.
110	Yerbes R, Lopez-Rivas A (2012). Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Invest New Drugs, 30, 541-7. DOI
111	Zhang S, Ding F, Luo A, et al (2007). XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther, 6, 973-80.
112	Zhuang J, Laing N, Oates M, et al (2014). Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Pharmacology Res Perspect, 2, 6.
113	Zou H, Henzel WJ, Liu X, et al (1997). Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90, 405-13. DOI
114	Bijangi-Vishehsaraei K, Saadatzadeh MR, Huang S, et al (2010). 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol Cell Biochem, 342, 133-42. DOI
115	Abedini MR, Muller EJ, Brun J, et al (2008). Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res, 68, 4511-7. DOI
116	Acehan D, Jiang X, Morgan DG, et al (2002). Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell, 9, 423-32. DOI
117	Albershardt TC, Salerni BL, Soderquist RS, et al (2011). Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem, 286, 24882-95. DOI
118	Bartholomeusz C, Itamochi H, Yuan LX, et al (2005). Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res, 65, 8406-13. DOI
119	Baud V, Karin M (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov, 8, 33-40. DOI
120	Boatright KM, Renatus M, Scott FL, et al (2003). A unified model for apical caspase activation. Mol Cell, 11, 529-41. DOI
121	Boeckler FM, Joerger AC, Jaggi G, et al (2008). Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A, 105, 10360-5. DOI
122	Bose P, Grant S (2013). Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep, 2, 12-4.
123	Bykov VJ, Issaeva N, Zache N, et al (2005a). Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem, 280, 30384-91. DOI
124	Bykov VJ, Wiman KG (2014). Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett, 588, 2622-7. DOI
125	Bykov VJ, Zache N, Stridh H, et al (2005b). PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene, 24, 3484-91. DOI
126	Calin GA, Cimmino A, Fabbri M, et al (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A, 105, 5166-71. DOI
127	Demma M, Maxwell E, Ramos R, et al (2010). SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem, 285, 10198-212. DOI
128	Day TW, Safa AR (2009). RNA interference in cancer: targeting the anti-apoptotic protein c-FLIP for drug discovery. Mini Rev Med Chem, 9, 741-8. DOI
129	de Almagro MC, Vucic D (2012). The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol, 34, 200-11.
130	De Cesare M, Perego P, Righetti SC, et al (2005). Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Eur J Cancer, 41, 1213-22. DOI
131	Devarajan E, Sahin AA, Chen JS, et al (2002). Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene, 21, 8843-51. DOI
132	Dineen SP, Roland CL, Greer R, et al (2010). Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res, 70, 2852-61. DOI
133	Duan H, Heckman CA, Boxer LM (2005). Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol, 25, 1608-19. DOI
134	Dubrez L, Berthelet J, Glorian V (2013). IAP proteins as targets for drug development in oncology. Onco Targets Ther, 9, 1285-304.
135	Duggan BJ, Maxwell P, Kelly JD, et al (2001). The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol, 166, 1098-105. DOI
136	Ichikawa K, Liu W, Zhao L, et al (2001). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med, 7, 954-60. DOI
137	Hu Y, Bebb G, Tan S, et al (2004). Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res, 10, 7662-70. DOI
138	Huerta S, Gao X, Livingston EH, et al (2010). In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery, 148, 346-53. DOI
139	Iancu-Rubin C, Mosoyan G, Glenn K, et al (2014). Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Exp Hematol, 42, 137-45. DOI
140	Jin Z, El-Deiry WS (2005). Overview of cell death signaling pathways. Cancer Biol Ther, 4, 139-63.
141	Kaminskyy VO, Surova OV, Piskunova T, et al (2013). Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling. Cell Death Dis, 4, 522. DOI ScienceOn
142	Kang MH, Reynolds CP (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 15, 1126-32. DOI
143	Kapoor P, Ramakrishnan V, Rajkumar SV (2012). Bortezomib combination therapy in multiple myeloma. Semin Hematol, 49, 228-42. DOI
144	Karami H, Baradaran B, Esfahani A, et al (2013). siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev, 14, 7719-24. DOI ScienceOn
145	Aron JL, Parthun MR, Marcucci G, et al (2003). Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood, 102, 652-8. DOI
146	Allegra D, Bilan V, Garding A, et al (2014). Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. Leukemia, 28, 2427.
147	Antonia SJ, Mirza N, Fricke I, et al (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 12, 878-87. DOI
148	Arbel N, Ben-Hail D, Shoshan-Barmatz V (2012). Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem, 287, 23152-61. DOI
149	Ashkenazi A, Pai RC, Fong S, et al (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104, 155-62. DOI ScienceOn
150	Atencio IA, Grace M, Bordens R, et al (2006). Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther, 13, 169-81. DOI
151	Azmi AS, Mohammad RM (2009). Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol, 218, 13-21. DOI
152	Baron AT, O'Bryant CL,Choi Y, et al (2011). Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI+/-bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). J Clin Oncol, 29, [Epub ahead of print].
153	Chauhan D, Velankar M, Brahmandam M, et al (2007). A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene, 26, 2374-80. DOI
154	Carter BZ, Mak DH, Morris SJ, et al (2011). XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis, 16, 67-74. DOI
155	Chang DW, Xing Z, Pan Y, et al (2002). c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. Embo J, 21, 3704-14. DOI
156	Chatterjee D, Schmitz I, Krueger A, et al (2001). Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res, 61, 7148-54.
157	Chen Y, Gao DY, Huang L (2014). In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv Drug Deliv Rev, 81, 128-41
158	Cheng Q, Ling X, Haller A, et al (2012). Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol, 3, 179-97.
159	Chi KN, Gleave ME, Klasa R, et al (2001). A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res, 7, 3920-7.
160	Chi SW (2014). Structural insights into the transcription-independent apoptotic pathway of p53. BMB Rep, 47, 167-72. DOI
161	Chipuk JE, Bouchier-Hayes L, Green DR (2006). Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ, 13, 1396-402. DOI
162	Feng W, Zhang B, Cai D, et al (2014). Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett, 347, 183-90. DOI ScienceOn
163	Eckelman BP, Salvesen GS, Scott FL (2006). Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep, 7, 988-94. DOI
164	Elmore S (2007). Apoptosis: a review of programmed cell death. Toxicol Pathol, 35, 495-516. DOI
165	Emi M, Kim R, Tanabe K, et al (2005). Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res, 7, 940-52. DOI ScienceOn
166	Fong PY, Xue WC, Ngan HY, et al (2006). Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J Clin Pathol, 59, 179-83. DOI
167	Fulda S (2009). Tumor resistance to apoptosis. Int J Cancer, 124, 511-5. DOI
168	Fulda S (2010). Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol, 2010, 370835.
169	Fulda S (2014). Molecular pathways: targeting inhibitor of apoptosis proteins in cancer-from molecular mechanism to therapeutic application. Clin Cancer Res, 20, 289-95. DOI
170	Fulda S, Debatin KM (2006). 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene, 25, 5125-33.
171	Galligan L, Longley DB, McEwan M, et al (2005). Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther, 4, 2026-36. DOI
172	Galluzzi L, Morselli E, Kepp O, et al (2010). Mitochondrial gateways to cancer. Mol Aspects Med, 31, 1-20. DOI
173	Khan KH, Blanco-Codesido M, Molife LR (2014). Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol Hematol, 90, 200-19. DOI
174	Karami H, Baradaran B, Esfehani A, et al (2014). Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide. Asian Pac J Cancer Prev, 15, 629-35. DOI
175	Kerr E, Holohan C, McLaughlin KM, et al (2012). Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ, 19, 1317-27. DOI
176	Kerr JF, Wyllie AH, Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 26, 239-57. DOI
177	Khosravi-Far R, Esposti MD (2004). Death receptor signals to mitochondria. Cancer Biol Ther, 3, 1051-7. DOI
178	Kinoshita H, Yoshikawa H, Shiiki K, et al (2000). Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer, 88, 986-91. DOI
179	Kitada S, Zapata JM, Andreeff M, et al (2000). Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96, 393-7.
180	Koschny R, Holland H, Sykora J, et al (2007). Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res, 13, 3403-12. DOI ScienceOn
181	Kroemer G, Dallaporta B, Resche-Rigon M (1998). The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol, 60, 619-42. DOI
182	Cohen EE, Rudin CM (2001). ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs, 2, 1770-5.
183	Chipuk JE, Kuwana T, Bouchier-Hayes L, et al (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 303, 1010-4. DOI ScienceOn
184	Chu ZL, McKinsey TA, Liu L, et al (1997). Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A, 94, 10057-62. DOI
185	Cimmino A, Calin GA, Fabbri M, et al (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A, 102, 13944-9. DOI
186	Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10, 704-14. DOI
187	Croci DO, Cogno IS, Vittar NB, et al (2008). Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem, 105, 381-90. DOI
188	Czabotar PE, Lessene G, Strasser A, et al (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol, 15, 49-63.
189	Dai DJ, Lu CD, Lai RY, et al (2005). Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroenterol, 11, 193-9. DOI
190	Dai Y, Liu M, Tang W, et al (2008). Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res, 14, 7701-10. DOI
191	Dai Y, Liu M, Tang W, et al (2009). A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer, 9, 392. DOI
192	Giaccone G, Zatloukal P, Roubec J, et al (2009). Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol, 27, 4481-6. DOI
193	Garofalo M, Condorelli GL, Croce CM, et al (2010). MicroRNAs as regulators of death receptors signaling. Cell Death Differ, 17, 200-8. DOI
194	Garofalo M, Croce CM (2011). microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol, 51, 25-43. DOI
195	Garofalo M, Quintavalle C, Di Leva G, et al (2008). MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 27, 3845-55. DOI
196	Green DR, Evan GI (2002). A matter of life and death. Cancer Cell, 1, 19-30. DOI
197	Greer RM, Peyton M, Larsen JE, et al (2011). SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-alpha-independent manner. Cancer Res, 71, 7640-8. DOI
198	Grillier-Vuissoz, Isabelle ea (2012). $PPAR{\gamma}$ -independent Activity of Thiazolidinediones: A Promising Mechanism of Action for New Anticancer Drugs. J Carcinogene Mutagene
199	Guicciardi ME, Gores GJ (2009). Life and death by death receptors. FASEB J, 23, 1625-37. DOI
200	Gustafsson AB, Gottlieb RA (2008). Heart mitochondria: gates of life and death. Cardiovasc Res, 77, 334-43.
201	Hamanaka RB, Bobrovnikova-Marjon E, Ji X, et al (2009). PERK-dependent regulation of IAP translation during ER stress. Oncogene, 28, 910-20. DOI
202	Leffers N, Lambeck AJ, Gooden MJ, et al (2009). Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer, 125, 2104-13. DOI
203	Kuball J, Schuler M, Antunes Ferreira E, et al (2002). Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther, 9, 833-43. DOI
204	Kudchadkar R, Ernst S, Chmielowski B, et al (2014). A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. Cancer Med [Epub ahead of print].
205	Lau R, Pratt MA (2012). The opposing roles of cellular inhibitor of apoptosis proteins in cancer. ISRN Oncol, 2012, 928120.
206	Lehmann S, Bykov VJ, Ali D, et al (2012). Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol, 30, 3633-9. DOI
207	Leonetti C, Biroccio A, D'Angelo C, et al (2007). Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate, 67, 1475-85. DOI
208	Li J, Yuan J (2008). Caspases in apoptosis and beyond. Oncogene, 27, 6194-206. DOI
209	Li LY, Luo X, Wang X (2001). Endonuclease G is an apoptotic DNase when released from mitochondria. Nature, 412, 95-9. DOI
210	Liedtke C, Zschemisch NH, Cohrs A, et al (2005). Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology, 129, 1602-15. DOI

11	Liying Hou. (2015) Molecular BioSystems T cells / 11 (11) , 3119
3	(2015) Molecular Medicine Reports Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma / 12 (3) , 4572
12	Abdul Anvesh Mansoori. (2015) Asian Pacific Journal of Cancer Prevention Molecular Links between Alcohol and Tobacco Induced DNA Damage, Gene Polymorphisms and Patho-physiological Consequences: A Systematic Review of Hepatic Carcinogenesis / 16 (12) , 4803
15	Aneta Rogalska. (2015) Asian Pacific Journal of Cancer Prevention Nuclear DNA Damage and Repair in Normal Ovarian Cells Caused by Epothilone B / 16 (15) , 6535
2	Jin Yang. (2015) International Journal of Rheumatic Diseases Inhibition of B-cell apoptosis is mediated through increased expression of Bcl-2 in patients with rheumatoid arthritis / 19 (2) , 134
4	Ling Liu. (2016) Journal of Biochemical and Molecular Toxicology -Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells / 30 (4) , 192
10	Maïté Fransolet. (2015) Journal of Assisted Reproduction and Genetics In vitro evaluation of the anti-apoptotic drug Z-VAD-FMK on human ovarian granulosa cell lines for further use in ovarian tissue transplantation / 32 (10) , 1551
5	(2015) Oncology Reports CD90 is upregulated in gastric cancer tissues and inhibits gastric cancer cell apoptosis by modulating the expression level of SPARC protein / 34 (5) , 2497
1	(2015) Oncology Reports Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway / 35 (1) , 447
3	(2016) Molecular Medicine Reports Suppression of c-FLIPL promotes JNK activation in malignant melanoma cells / 13 (3) , 2904
4	(2016) Molecular Medicine Reports Lycopene inhibits the cell proliferation and invasion of human head and neck squamous cell carcinoma / 14 (4) , 2953
18	Arkadiusz Gajek. (2016) Asian Pacific Journal of Cancer Prevention Early Activation of Apoptosis and Caspase-independent Cell Death Plays an Important Role in Mediating the Cytotoxic and Genotoxic Effects of WP 631 in Ovarian Cancer Cells / 16 (18) , 8503
2	Monika Paul-Samojedny. (2016) BioDrugs Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells / 30 (2) , 129
1	(2016) Oncology Reports Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1 / 36 (1) , 49
6	Liying Guo. (2016) Oncology Reports Pterostilbene inhibits hepatocellular carcinoma through p53/SOD2/ROS-mediated mitochondrial apoptosis / 36 (6) , 3233
2	Jun Dong. (2016) Tumor Biology Influence of the interaction between long noncoding RNAs and hypoxia on tumorigenesis / 37 (2) , 1379
6	Hongchen Zhang. (2016) Tumor Biology Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma / 37 (6) , 8305
6	Yaping Yang. (2016) Scanning Disulfiram chelated with copper promotes apoptosis in human breast cancer cells by impairing the mitochondria functions / 38 (6) , 825
3	(2016) International Journal of Oncology Lentivirus-mediated downregulation of MAT2B inhibits cell proliferation and induces apoptosis in melanoma / 49 (3) , 981
4	(2016) International Journal of Oncology Caudatin targets TNFAIP1/NF-κB and cytochrome c/caspase signaling to suppress tumor progression in human uterine cancer / 49 (4) , 1638
5	(2016) International Journal of Oncology miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes / 49 (5) , 1921
6	De Cai. (2016) Cancer Chemotherapy and Pharmacology YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo / 77 (6) , 1217
2	(2017) British Journal of Dermatology Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway / 177 (2) , 456
11	(2017) Apoptosis The induction of apoptosis and autophagy in human hepatoma SMMC-7721 cells by combined treatment with vitamin C and polysaccharides extracted from Grifola frondosa / 22 (11) , 1461
2	Hui Li. (2017) Acta Pharmacologica Sinica Oblongifolin C and guttiferone K extracted from Garcinia yunnanensis fruit synergistically induce apoptosis in human colorectal cancer cells in vitro / 38 (2) , 252
6	(2017) Tumor Biology Biological evaluation of octahydropyrazin[2,1-a:5,4-a′]diisoquinoline derivatives as potent anticancer agents / 39 (6) , 101042831770164
3	(2017) Molecular Biology Reports CADASIL mutant NOTCH3(R90C) decreases the viability of HS683 oligodendrocytes via apoptosis / 44 (3) , 273
2	Yi Xu. (2017) Journal of Physiology and Biochemistry Anti-proliferative effects of paeonol on human prostate cancer cell lines DU145 and PC-3 / 73 (2) , 157
1663-9812	(2017) Frontiers in Pharmacology Rumex dentatus Inhibits Cell Proliferation, Arrests Cell Cycle, and Induces Apoptosis in MDA-MB-231 Cells through Suppression of the NF-κB Pathway / 8 (1663-9812)
11	(2015) International Journal of Molecular Sciences Chondrocyte Apoptosis in the Pathogenesis of Osteoarthritis / 16 (11) , 26035
5	Joana Pereira. (2016) Molecules An Aqueous Extract of Tuberaria lignosa Inhibits Cell Growth, Alters the Cell Cycle Profile, and Induces Apoptosis of NCI-H460 Tumor Cells / 21 (5) , 595
12	Xiao-qin Lv. (2016) Acta Pharmacologica Sinica Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP / 37 (12) , 1574
3	(2017) Oncology Reports MHY451 induces cell cycle arrest and apoptosis by ROS generation in HCT116 human colorectal cancer cells / 38 (3) , 1783
2	(2018) International Journal of Molecular Sciences Apoptosis: A Target for Anticancer Therapy / 19 (2) , 448
2	(2018) Molecules Physicochemical Characterization and Functional Analysis of the Polysaccharide from the Edible Microalga Nostoc sphaeroides / 23 (2) , 508
1532-2807	(2019) Pathology & Oncology Research The Role of Caspase Genes Polymorphisms in Genetic Susceptibility to Philadelphia-Negative Myeloproliferative Neoplasms in a Portuguese Population / (1532-2807)
3	(2015) Oncology Letters Overexpression of short TRPM8 variant α promotes cell migration and invasion, and decreases starvation-induced apoptosis in prostate cancer LNCaP cells / 10 (3) , 1378
4	Hua Yang. (2016) Cancer Biotherapy and Radiopharmaceuticals Decreased LRIG1 in Human Ovarian Cancer Cell SKOV3 Upregulates MRP-1 and Contributes to the Chemoresistance of VP16 / 31 (4) , 125
2	(2017) Molecular Medicine Reports Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis / 16 (2) , 1530
12	(2017) Arquivos de Neuro-Psiquiatria High expression of XIAP and Bcl-2 may inhibit programmed cell death in glioblastomas / 75 (12) , 875
5	(2018) Biotechnic & Histochemistry extract in HeLa and MDA-MB-231 cells by a caspase-3 pathway / 93 (5) , 311
1942-0994	(2018) Oxidative Medicine and Cellular Longevity ): A Comprehensive Mechanistic Review / 2018 (1942-0994) , 1
2211-3436	(2019) Cellular Oncology The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival / (2211-3436)
4	(2019) International Journal of Molecular Sciences Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy / 20 (4) , 959
02724391	(2019) Drug Development Research Mechanisms underlying isoliquiritigenin-induced apoptosis and cell cycle arrest via ROS-mediated MAPK/STAT3/NF-κB pathways in human hepatocellular carcinoma cells / (02724391)
2234-943X	(2019) Frontiers in Oncology Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers / 9 (2234-943X)
12	(2018) The FASEB Journal Delivery of a TNF-α–derived peptide by nanoparticles enhances its antitumor activity by inducing cell-cycle arrest and caspase-dependent apoptosis / 32 (12) , 6948
1573-7330	(2019) Journal of Assisted Reproduction and Genetics Evaluation of Z-VAD-FMK as an anti-apoptotic drug to prevent granulosa cell apoptosis and follicular death after human ovarian tissue transplantation / (1573-7330)
00219541	(2018) Journal of Cellular Physiology Key microRNAs in the biology of breast cancer; emerging evidence in the last decade / (00219541)
2	(2018) Acta Pharmaceutica Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3 / 68 (2) , 211
2	(2019) Nanoscale Development of an advanced nanoformulation for the intracellular delivery of a caspase-3 selective activity-based probe / 11 (2) , 742